Progress in the development of therapeutic antibodies targeting prion proteins and β-amyloid peptides  

作　　者：HE JinSheng1, ZHANG Ying1 & HONG Tao1,2 1College of Life Sciences and Bioengineering, School of Science, Beijing Jiaotong University, Beijing 100044, China 2Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100052, China 

出　　处：《Science China(Life Sciences)》2010年第8期959-963,共5页中国科学（生命科学英文版）

基　　金：supported by the National High Technology Research and Development Program of China (Grant No. 2006AA02A247);the Scientific and Technological Major Special Project of China (Grant No. 2009ZX10004-216)

摘　　要：Prion diseases and Alzheimer’s disease (AD) are characterized by protein misfolding, and can lead to dementia. However, prion diseases are infectious and transmissible, while AD is not. The similarities and differences between these diseases have led researchers to perform comparative studies. In the last 2 decades, progress has been made in immunotherapy using anti-prion protein and anti-β-amyloid antibodies. In this study, we review new ideas and strategies for therapeutic antibodies targeting prion diseases and AD through conformation dependence.Prion diseases and Alzheimer’s disease (AD) are characterized by protein misfolding, and can lead to dementia. However, prion diseases are infectious and transmissible, while AD is not. The similarities and differences between these diseases have led researchers to perform comparative studies. In the last 2 decades, progress has been made in immunotherapy using anti-prion protein and anti-β-amyloid antibodies. In this study, we review new ideas and strategies for therapeutic antibodies targeting prion diseases and AD through conformation dependence.

关 键 词：PRION Alzheimer’s disease IMMUNOTHERAPY ANTIBODY CONFORMATION 

分 类 号：R749.16[医药卫生—神经病学与精神病学]